Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Results of Emisphere Technologies, Inc. Phase II Patient Trial Were Presented Today at the XVIIth Congress of the International Society of Thrombosis and Haemostasis and Showed Oral Heparin to be Comparable in Safety and Activity to Subcutaneous Heparin
Results of Emisphere Technologies, Inc. Phase II Patient Trial Were Presented Today at the XVIIth Congress of the International Society of Thrombosis and Haemostasis and Showed Oral Heparin to be Comparable in Safety and Activity to Subcutaneous Heparin Tarrytown, NY, August 19, 1999 --- Emisphere
View HTML
Toggle Summary Emisphere Technologies, Inc. Announces the Presentation of its Phase II Oral Heparin Results
Emisphere Technologies, Inc. Announces the Presentation of its Phase II Oral Heparin Results To be presented at the XVIIth Congress of the International Society of Thrombosis and Haemostasis-August 19, 1999 Tarrytown, NY August 17, 1999 - Emisphere Technologies, Inc.
View HTML
Toggle Summary Emisphere Announces Restructuring of Relationship with Elan Corporation for Development and Marketing of Oral Heparin
Emisphere Announces Restructuring of Relationship with Elan Corporation for Development and Marketing of Oral Heparin Tarrytown, NY, July 6, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced it has agreed with Elan Corporation, plc (NYSE: ELN) to restructure their 50-50 joint
View HTML
Toggle Summary Emisphere Reports 1999 Third Quarter and Nine Month Financial Results
Emisphere Reports 1999 Third Quarter and Nine Month Financial Results Tarrytown, NY, June 11, 1999 --- Emisphere Technologies, Inc. (NASDAQ: EMIS) today reported financial results for the third quarter and nine months ended April 30, 1999. Contract research revenues for the third quarter ended
View HTML
Toggle Summary Emisphere Appoints New Chief Financial Officer and New Director of Research
Emisphere Appoints New Chief Financial Officer and New Director of Research Tarrytown, NY, April 13, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Charles H. Abdalian, Jr. has joined the Company as Chief Financial Officer, a newly created position, and that Steven M.
View HTML
Toggle Summary Emisphere Reports 1999 Second Quarter and Six Month Financial Results
Emisphere Reports 1999 Second Quarter and Six Month Financial Results Tarrytown, NY and Dublin, Ireland, March 17, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported financial results for the second quarter and six months ended January 31, 1999.
View HTML
Toggle Summary Emisphere Announces Update on Oral Heparin Development Program
Emisphere Announces Update on Oral Heparin Development Program Tarrytown, NY, February 25, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported on a number of key events in their oral heparin program. First, the manufacturing process for the Emisphere carrier has been successfully
View HTML
Toggle Summary Emisphere Announces Spinout of a New Drug Development Company
Emisphere Announces Spinout of a New Drug Development Company Tarrytown, NY and Dublin, Ireland, January 13, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will form a new subsidiary company to explore the development of a novel drug design technology.
View HTML
Toggle Summary Emisphere and Elan Announce Positive Phase II Clinical Trial Results for Oral Heparin Product
Emisphere and Elan Announce Positive Phase II Clinical Trial Results for Oral Heparin Product Hawthorne, NY and Dublin, Ireland, January 11, 1999 --- Emisphere Technologies, Inc. (Nasdaq: NMS: EMIS) and Elan Corporation, plc (NYSE: ELN) announced that the preliminary results of the Phase II oral
View HTML
Toggle Summary Emisphere Reports 1998 Fourth Quarter and Year End Financial Results
Emisphere Reports 1998 Fourth Quarter and Year End Financial Results Hawthorne, NY, October 27, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported fourth quarter and year end financial results for the period ended July 31, 1998. Net loss for the fourth quarter of 1998 was $3.4
View HTML
Toggle Summary Lilly and Emisphere Announce Osteoporosis Compound to Enter Clinical Trials
Lilly and Emisphere Announce Osteoporosis Compound to Enter Clinical Trials Indianapolis, IN, and Tarrytown, NY September 3, 1998 --- Eli Lilly & Co. (NYSE: LLY) and Emisphere Technologies, Inc. (Nasdaq: NMS: EMIS) announced today that Lilly has formally selected a proprietary Emisphere carrier for
View HTML
Toggle Summary Emisphere and Elan Contribute $10 Million to Heparin Joint Venture
Emisphere and Elan Contribute $10 Million to Heparin Joint Venture Tarrytown, NY, August 5, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) announced today that Emisphere and Elan Corporation plc have contributed $10 million ($5 million each) to their 50-50 joint venture to develop oral
View HTML
Toggle Summary Emisphere Reports 1998 Third Quarter and Nine Month Financial Results
Elan Makes Additional $4 Million Investment in Emisphere Through Warrant Exercise
View HTML
Toggle Summary Emisphere Announces Initiation of Phase II Clinical Trial for Oral Heparin Product
Emisphere Announces Initiation of Phase II Clinical Trial for Oral Heparin Product Hawthorne, NY, May 27, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today it has initiated a Phase II clinical study for its oral heparin product for the prevention of deep vein thrombosis.
View HTML
Toggle Summary Emisphere Announces New Senior Vice President of Clinical Affairs
Emisphere Announces New Senior Vice President of Clinical Affairs Hawthorne, NY, May 20, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Barry B. Kanarek, M.D., Ph.D., has joined the Company as Senior Vice President of Clinical Affairs, a newly created position. Dr.
View HTML